|
|
 |
|
Viewing report
|
|
|
|
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Nov 2011, Pages: 102
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), were approved in the US. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the US despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.
Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but is significantly higher in Japan (18.4%). This disparity across geographical markets exists because of the variation in the approval dates for some of the drugs in the US, Europe and Japan. In the US, therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved, whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, and its acceptance across Europe is predicted to represent a growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have a similar mode of action to that of existing drugs, and are therefore unlikely to impact the market significantly.
During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the decline in the market valuations due to patent expiries of these drugs is likely to be compensated by the new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will register growth through 2010 to 2018.
Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitors, selective alpha2A-adrenergic receptor agonists, serotonin-norepinephrine-dopamine reuptake inhibitors, selective serotonin (5-HT1)-dopamine antagonists, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitors (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonists, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonists, alpha7 NNR agonists, serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonists, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonists, histamine H3 receptor antagonists, selective alpha2A-adrenergic receptor agonists, histamine H3 autoreceptor antagonists, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitors, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonists.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
